Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Waters posts solid revenue growth but swings to a GAAP loss on acquisition costs.

What the company is saying

Waters Corporation frames its second quarter 2026 results as a clear outperformance, emphasizing that total reported revenue of $1.645 billion surpassed the high end of its guidance. The announcement highlights organic revenue growth of 7% as reported and 9% in constant currency, and points to $817 million in Biosciences and Diagnostic Solutions revenue exceeding guidance by $15 million. The company stresses broad-based divisional growth, with each major segment posting higher revenues versus the prior year comparable period. Leadership, specifically President & CEO Udit Batra, Ph.D., is referenced as the institutional face of the results, though no individual commentary is quoted. The tone is upbeat and confident, repeatedly referencing raised guidance for full-year 2026 and the strength of end-market conditions. While the narrative is focused on revenue and adjusted EPS growth, the announcement downplays the negative GAAP EPS and omits discussion of cash flow, margins, or integration costs.

What the data suggests

The data shows Waters delivered $1.645 billion in total reported revenue for Q2 2026, exceeding its own guidance. Organic revenue reached $828 million, up 7% as reported and 9% in constant currency. Acquired Biosciences and Diagnostic Solutions businesses contributed $817 million, growing 4% year-over-year and beating guidance by $15 million. The Analytical Sciences Division posted $669 million, up from $627 million, while Biosciences and Advanced Diagnostics divisions also grew to $368 million and $449 million, respectively. Adjusted EPS increased 3% to $3.05, but GAAP diluted EPS swung to a loss of ($1.39) from a profit of $2.47 a year earlier, reflecting acquisition-related charges. The company raised its full-year 2026 guidance, now targeting 7–9% organic constant currency revenue growth, $3.045 billion in acquired business revenue, and adjusted EPS of $14.45–$14.65, representing 10–12% growth. Despite the positive revenue and adjusted EPS trends, the lack of cash flow, margin, or cost disclosures limits insight into underlying profitability and integration risks.

Analysis

The announcement is upbeat, highlighting revenue and adjusted EPS growth, and raising full-year guidance. The narrative emphasizes outperformance versus guidance and broad-based growth, but the actual realised progress is moderate: adjusted EPS grew only 3% year-over-year, and GAAP EPS swung to a loss, likely due to acquisition-related charges. While revenue and adjusted EPS are disclosed, there is no information on cash flow, margins, or the sustainability of growth. A significant portion of the announcement is forward-looking, with raised guidance for the remainder of 2026, but these are projections rather than realised results. The acquisition of new businesses is capital intensive, and the benefits are not immediate, as evidenced by the negative GAAP EPS. The gap between narrative and evidence is most pronounced in the optimistic framing of guidance and the lack of detail on profitability or integration costs.

Risk flags

• ●GAAP EPS swung from $2.47 in Q2 2025 to a loss of ($1.39) in Q2 2026, indicating that acquisition-related charges or other costs are materially impacting reported profitability. This matters because it raises questions about the true economic benefit of the acquisitions and the sustainability of adjusted earnings.
• ●No cash flow, gross margin, or detailed cost disclosures are provided, making it impossible to assess the quality of earnings or the company's ability to convert revenue growth into free cash flow. This lack of transparency increases uncertainty for investors seeking to understand underlying financial health.
• ●The company claims 'all components' of guidance are raised and references 'broad strengthening in end-market conditions,' but provides no supporting numerical evidence for these assertions. This gap between narrative and data introduces a risk that the optimism is not fully grounded in measurable results.
• ●Acquisition-related purchase accounting charges are referenced but not quantified, and the impact on future quarters is not discussed. If these charges persist or integration proves more costly than anticipated, future GAAP profitability could remain under pressure.

Bottom line

Waters Corporation delivered revenue and adjusted EPS growth in Q2 2026, outperforming its own guidance and raising expectations for the remainder of the year. The company’s upbeat narrative is partially supported by realised revenue gains across all major divisions and a 3% increase in adjusted EPS, but the swing to a GAAP loss highlights the material impact of acquisition-related costs. The absence of cash flow, margin, or detailed cost data leaves a significant gap in assessing the sustainability of growth and the true profitability of the business. Investors should view the raised guidance as a positive signal, but the lack of transparency on integration costs and profitability metrics tempers the strength of the story. To materially strengthen the investment case, Waters would need to disclose cash flow and margin trends alongside its headline results. The most important takeaway: revenue momentum is real, but the underlying economics remain unclear without fuller disclosure.

Announcement summary

(NYSE: WAT) Waters Corporation announced its financial results for the second quarter of 2026, reporting total revenue of $1.645 billion, which surpassed the high end of the guidance range. Organic revenue was $828 million, representing 7% growth as reported and 9% in constant currency, while revenue from the acquired Biosciences and Diagnostic Solutions businesses was $817 million, exceeding guidance by $15 million. The Analytical Sciences Division delivered reported revenue of $669 million, the Biosciences Division $368 million, the Advanced Diagnostics Division $449 million, the Clinical Business Unit $72 million, and the Materials Sciences Division $87 million. GAAP diluted loss per share was ($1.39), compared to diluted EPS of $2.47 for the second quarter of 2025, while adjusted EPS grew 3% to $3.05, compared to $2.95 for the second quarter of 2025. The company is raising all components of its full-year 2026 guidance, now expecting organic constant currency revenue growth of 7% to 9%, acquired business reported revenue of $3.045 billion, and adjusted EPS of $14.45 to $14.65, reflecting 10-12% growth. For the third quarter of 2026, Waters expects organic constant currency revenue growth of 8% to 10%, acquired business reported revenue of approximately $895 million, and adjusted EPS of $3.95 to $4.05. Waters Corporation will webcast its second quarter 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time.

Disagree with this article?